BioGaia has signed an agreement with Dong Sung Pharmaceutical Company Ltd, for
the exclusive rights to sell BioGaia’s ProTectis baby drops and ProTectis and
Gastrus tablets through the retail pharmacy channel in South Korea from 2013.
The products will be sold under BioGaia’s own brand.
Dong Sung is a leading South Korean pharmaceutical manufacturer founded in 1957.
The company was made public in 1990 and has a large medical sales force visiting
paediatricians and internists, including gastroenterologists.
The partnership with Dong Sung will significantly improve BioGaia’s existing
distribution coverage in South Korea with sales through the retail pharmacy
channel. BioGaia’s existing partner will continue covering the multi-level
marketing channel.
Both the BioGaia ProTectis baby drops and the BioGaia ProTectis tablets contain
BioGaia’s patented and well researched probiotic strain Lactobacillus reuteri
Protectis. Today BioGaia’s finished products are available in around 60
countries. BioGaia Gastrus is a new product that is currently being investigated
in patients with Helicobacter pylori infection.
“We are pleased with the new agreement as it means that our products will be
available in our traditional distribution channel in a market with good
potential; South Korea has 50 million inhabitants and is ranked as the country
with the 15th strongest purchasing power in the world”, says Peter Rothschild,
Chief Executive Officer, BioGaia.
Latest press releases from BioGaia
2013-04-26 Annual general Meeting of BioGaia
2013-04-26 BioGaia AB Interim report 1 January-31 March 2013
2013-03-21 Notice to attend the Annual General Meeting of BioGaia AB
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 7 May 2013, 2:00 pm
CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
